Amazing Facts 24

Oncopeptides publishes Q2 report 2022

Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, publishes the report for the second quarter 2022.

“CHMPs recommendation to grant Pepaxti a full marketing authorization approval in EU is foundational for Oncopeptides says Jakob Lindberg, CEO of Oncopeptides. “This is excellent news for patients, shareholders, and for the future development of Oncopeptides.”

Financial overview April-June

Financial overview January-June

Significant events April-June 

Events after the period

Exit mobile version